stockportfolio.pro
Stocks / GYRE vs TLRY
GYRE vs TLRY
Gyre Therapeutics, Inc. and Tilray Brands, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Gyre Therapeutics, Inc. (GYRE) | Tilray Brands, Inc. (TLRY) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $116.59M | $821.31M |
| Net income (latest FY) | $5.03M | $-2.19B |
| Revenue growth (5y CAGR) | 41.0% | 31.3% |
| Net margin | 4.3% | -266.3% |
| Return on equity | 4.7% | -144.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GYRE — free Open TLRY — freeFrequently asked questions
Which is bigger, GYRE or TLRY?
Tilray Brands, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, GYRE or TLRY?
Over the last five fiscal years, Gyre Therapeutics, Inc. grew revenue faster — 41.0%/yr versus 31.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.